United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade) [Seeking Alpha]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Seeking Alpha
Ralinepag's blockbuster potential, TYVASO's IPF expansion, and a strategic shift away from royalty-heavy products underpin UTHR's attractive valuation. My base case fair value is ~$590/share, with scenario analysis indicating a solid margin of safety and upside toward $800 in bullish conditions. Risks include execution on ralinepag transition, TYVASO's IPF role, and the challenge of replicating pipeline success, but UTHR's profitability and growth remain compelling. narvo vexar/iStock via Getty Images Overview Although it has been two and a half years since my last write-up on United Therapeutics Corporation's ( UTHR stock, PAH is a space I've been following closely. So, when the company uncovered This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (UTHR) had its price target raised by Cantor Fitzgerald from $525.00 to $625.00. They now have an "overweight" rating on the stock.MarketBeat
- Asylon Robotics Announces New Advisors, Additions to Leadership Team [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of MedicineBusiness Wire
- United Therapeutics Corporation (UTHR) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- 3/10/26 - Form 4
- UTHR's page on the SEC website